Loren Data's SAM Daily™

FBO DAILY ISSUE OF JUNE 07, 2003 FBO #0555
SOLICITATION NOTICE

A -- Continuation of the Effect of Pyridinio Alkanlyl Thidesteers in Primates

Notice Date

6/5/2003
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-30067-NG
 

Response Due

6/20/2003
 

Archive Date

7/5/2003
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
 

E-Mail Address

holdcram@exchange.nih.gov, rs442i@nih.gov
 

Description

The National Institutes of Health (NIH), National Cancer Institute (NCI), Chemical Immunology Section of the Laboratory of Cell Biology (LCB), intends to procure on a sole source basis with the University of Pittsburgh, 3109 Cathedral of Learning Pittsburgh, PA 15260, services to test the in vivo efficacy of novel pyridinioalkanoyl thioester (PATE) compounds developed by the LCB using the non-human primate model of human immunodeficiency virus (HIV) infection established at the University of Pittsburgh. The supplies and services herein are being procured in accordance with simplified acquisition procedures authorized by FAR Part 13. The North American Industry Classification System Code is 541710 and the business size standard is 500 employees. The Chemical Immunology Section of LCB has been involved in AIDS research for several years. The Section synthesizes novel compounds targeted to retroviral nucleocapsid proteins and determines their suitability as drugs for treating infections with HIV-1 or other retroviruses. The University of Pittsburgh Primate Facility for Infectious Disease Research has performed PATE compound efficacy studies using the SIV cynomolgus monkey model. The studies are pilot experiments and are designed to address whether administration of PATE compounds at two different doses for a short time period is effective at reducing viral load when compared to animals infected but not treated with drugs. Virus loads will be determined using real-time RT-PCR by the Murphey-Corb Laboratory. The University of Pittsburgh has provided preclinical in vivo evaluations which are essential to further the development of novel NCp7 inhibitors and advancement to clinical testing under a previous contract awarded by the NCI. Contractor shall provide a report to LCB with data on virus load in treated animals; and shall measure drug toxicity. The University of Pittsburgh Primate Facility for Infectious Disease Research is a state-of-the-art facility that has expertise in non-human primate models of HIV using the SIV model. Dr. Barratt-Boyes is an expert in cellular vaccines for SIV and the study of dendritic cells, which are essential cells in the generation of antiviral immune responses. Dr. Murphey-Corb is the director of the facility with 20 years experience working in the SIV/rhesus macaque model, with interests in DNA vaccination for SIV. Dr. Murphey-Corb's laboratory has developed a highly sensitive assay to reproducibly detect low levels of circulating virus by real time reverse transcriptase polymerase chain reaction (RT-PCR). In the past twelve months, Dr. Murphey-Corb has developed the cynomolgus monkey as a valid non-human primate model for SIV infection. This model provides an ideal experimental infection with which to test the efficacy of PATE compounds that is highly related to the natural HIV infection of humans. Dr's. Barratt-Boyes and Murphey-Corb are uniquely qualified to provide the required services with their expertise in the SIV/non-human primate model. Period of Performance: upon award of purchase order through 12 months with one (1) option not to exceed 10 months. FAR Clause 52.217-8 Option to Extend Services (November 1999) and 52.217-9 Option to Extend the Term of the Contract (March 2000) applies to this order. Changing variables at this time will interrupt correct interpretation of current experiment in progress. This is not a solicitation for competitive quotations. However, if any interested party believes it can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI researcher to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statements must be received in the Contracting Office by 1:00 PM EDT (local Washington, D.C. time) on June 20, 2003. If you have any questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@exchange.nih.gov or by fax (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.
 

Place of Performance

Address: NIH

Zip Code: 20892

Country: USA
 

Record

SN00340669-W 20030607/030605213250 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |